Vimarsana
Biggest News Aggregation in the World

Page 8 - Toby Maher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Toby Maher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Toby Maher Today - Breaking & Trending Today

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference - Vimarsana News

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
PureTech Announces Annual Results for Year Ended December 31, 2021 - Vimarsana News

PureTech Announces Annual Results for Year Ended December 31, 2021

PureTech Announces Annual Results for Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace

Vicore to host R&D Day - Vimarsana News

Vicore to host R&D Day

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...

Vicore Pharma Holding AB: Vicore to host R&D Day - Vimarsana News

Vicore Pharma Holding AB: Vicore to host R&D Day

GOTHENBURG, Sweden, March 4, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - Vimarsana News

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of...